To include your compound in the COVID-19 Resource Center, submit it here.

Ibrance failure in adjuvant breast cancer opens door for Novartis, Lilly

Pfizer sheds billions in valuation on Ibrance failure in early-stage breast cancer

The failure of Pfizer’s second-best-selling drug Ibrance in a pivotal trial as an adjuvant treatment for breast cancer opens a window for rival drugs in an indication that could have been a major growth opportunity for the pharma.

The miss

Read the full 392 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE